MedTrace Logo

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

NCT04518137 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-01-31

No results posted yet for this study

Summary

This is a single-arm and open-label study of ATG-008 for the Treatment of Patients With advanced Solid Tumors harboring NFE 2L2, STK11, RICTOR or other specific genetic alterationts

Conditions

Interventions

DRUG

ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle

48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle

Sponsors & Collaborators

  • Shanghai Antengene Corporation Limited

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi, MD; PhD · Chinese Academay of Medical Science and Peking Union Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-09
Primary Completion
2022-05-30
Completion
2022-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04518137 on ClinicalTrials.gov